1
Clinical Trials associated with Allogeneic CAR-T targeting CD70(Nanjing Calmhome Cell & Gene Engineering Institute) / RecruitingEarly Phase 1 A Single-arm, Open, Exploratory Clinical Study of Allogeneic CAR-T Cells in the Treatment of Relapsed/Refractory Brain Gliomas With Positive CD70 Expression
The goal of this clinical trial is to learn if allogeneic CAR-T cells can treat patients with advanced gliomas. The main questions it aims to answer are:
Evaluate the safety of allogeneic CAR-T cells in the treatment of advanced gliomas.
To evaluate the effectiveness of allogeneic CAR-T cells in the treatment of advanced gliomas and to study its immunological properties in patients.
100 Clinical Results associated with Allogeneic CAR-T targeting CD70(Nanjing Calmhome Cell & Gene Engineering Institute)
100 Translational Medicine associated with Allogeneic CAR-T targeting CD70(Nanjing Calmhome Cell & Gene Engineering Institute)
100 Patents (Medical) associated with Allogeneic CAR-T targeting CD70(Nanjing Calmhome Cell & Gene Engineering Institute)
100 Deals associated with Allogeneic CAR-T targeting CD70(Nanjing Calmhome Cell & Gene Engineering Institute)